Pharmafile Logo
Pharmafocus logo
Advanced Search

ITP

Showing 3 posts of 3 posts found.

Novartis receives EU approval for blood disorder treatment in children

April 7, 2016
Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp

Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …

News
Blog footer

Digital Pharma: Amgen’s online village

June 16, 2010
Medical Communications Amgen, ITP, community, disease awareness campaigns

Amgen has launched an online community for European healthcare professionals, patients and carers affected by autoimmune disease immune thrombycytopenia. Styled …

News

NICE rejects GSK’s Revolade

June 10, 2010
Sales and Marketing ITP, NICE, Revolade

NICE has rejected GlaxoSmithKline’s Revolade saying in draft guidance that the blood disorder drug’s benefits were unclear. The watchdog assessed …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026